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5Introductory note and acknowledgements
Three in-depth reviews of topical interest are published as ‘Selected issues’ each year. These reports are based on information 
provided to the EMCDDA by the EU Member States and candidate countries and Norway (participating in the work of the 
EMCDDA since 2001) as part of the national reporting process. This report also includes data from the database produced 
within the European school survey project on alcohol and other drugs (ESPAD), a collaborative European project coordinated 
by the Swedish Council for Information on Alcohol and Other Drugs (CAN). It is written in line with the rules for the use of the 
ESPAD database. For a list of national institutions and supporting organisations for the other countries see www.espad.org.
The three issues selected for 2009 are:
•  Drug offences: sentencing and other outcomes;
•  Polydrug use: patterns and responses;
•  Trends in injecting drug use.
All ‘Selected issues’ (in English) and summaries (in 23 languages) are available on the EMCDDA website: 
http://www.emcdda.europa.eu/publications/selected-issues.
The EMCDDA would like to thank the following for their help in producing this ‘Selected issue’:
•  the heads of Reitox national focal points and their staff;
•  the services within each Member State that collected the raw data;
•  the members of the Management Board and the Scientific Committee of the EMCDDA;
•  the Swedish Council for Information on Alcohol and Other Drugs (CAN) and the European School Survey Project on 
Alcohol and Other Drugs (ESPAD) and its national principal investigators;
•  the Office for Official Publications of the European Communities;
•  Magenta Publishing.
Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The network is comprised of national focal points in the EU 
Member States, Norway, the candidate countries and at the European Commission. Under the responsibility of their governments, 
the focal points are the national authorities providing drug information to the EMCDDA.
The contact details of the national focal points may be found at:  
http://www.emcdda.europa.eu/about/partners/reitox-network

7Introduction
A combination of population- and substance-specific 
approaches has framed the monitoring of illicit drugs use 
during the last decades. Our knowledge of the drug 
phenomenon is largely based on surveys conducted among 
the general population and specific groups, and on data 
from treatment centres. These data show, for example, that 
cannabis use mainly occurs during adolescence and young 
adulthood, that ecstasy can be associated with certain 
lifestyles and activities, and that heroin use frequently results 
in marginalisation and major health problems. These 
approaches have improved our understanding of the 
diversity of drug use patterns and of drug user profiles, and 
suggested better frameworks for planning and evaluating 
drug-related interventions targeting populations with 
sometimes very different problems and needs. 
In contrast, the understanding of multiple substance use and 
the analysis of overlaps between different drug-using 
populations, such as cannabis users and binge alcohol 
drinkers or partygoers and dependent drug users, have 
been more limited. This has become particularly apparent in 
recent years, as increasing prevalence levels of drug use 
(e.g. alcohol, cannabis and cocaine) have translated into 
additional populations of drug users, and as an increasing 
range of available substances has resulted in additional 
drug combination possibilities. In such a context, the 
limitations of substance-specific approaches to 
understanding drug use patterns and trends have become 
increasingly apparent. 
To fine-tune existing drug policies and drug-related 
interventions, it is necessary to explore the complexity of 
drug use patterns and consequences. Polydrug use — a 
pattern that has already been observed in many drug-using 
populations — is a priority for investigation. One simple 
rationale for this is that all pharmaceutical drug use follows 
the general rule that drug combinations tend to increase the 
risks of adverse health effects. Such effects can occur 
(generally as acute toxicity) shortly after the consumption of 
several substances, or within a short time. They can also 
occur following a long period of use, due to various 
mechanisms affecting body systems, including the liver and 
the central nervous, cardiovascular or respiratory systems 
(McCabe et al., 2006; Macleod et al., 2004; Stefanis and 
Kokkevi, 1986). Intensive alcohol use is often a major, but 
overlooked, component of polydrug use. For example, 
stimulant drugs such as cocaine may enable users to 
consume large quantities of alcohol over longer periods than 
would otherwise be possible. 
While it is relatively easy to show that polydrug use can 
lead to multiple adverse health consequences, studying it 
remains a challenge, both at the conceptual and at the 
practical levels. Conceptually, polydrug use encompasses 
wide variations in user populations and patterns of use: from 
occasional alcohol and cannabis use to the daily use of 
combinations of heroin, cocaine, alcohol and 
benzodiazepines. As a result, it is not possible to arrive at a 
single definition of polydrug use, which would be necessary 
to develop standardised measures. Understanding polydrug 
use also requires a focus on the use of a range of drugs by 
the individual; but most drug monitoring information remains 
substance-specific and reported as aggregated national 
data. To overcome some of these difficulties, this ‘Selected 
issue’ looks at three different populations, for which patterns 
of polydrug use and their consequences are likely to differ: 
adolescents aged 15–16 years, young adults and problem 
drug users. 
Polydrug use: patterns and responses
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Polydrug use among adolescents
Use of alcohol, cigarettes, cannabis and other psychoactive 
substances by young Europeans has increased since the 
1990s, in a variety of drug-using repertoires (EMCDDA, 
2008a). School population surveys invariably show that 
alcohol consumption and cigarette smoking are far more 
prevalent than the use of illicit drugs. They also confirm that 
cannabis is the most commonly used illicit drug, with 
prevalence estimates generally reaching much higher levels 
than those for other substances such as ecstasy, 
amphetamine, cocaine, heroin, LSD and hallucinogenic 
mushrooms.
Intensive patterns of drug use, with the possible exception of 
tobacco smoking, usually remain limited among adolescents. 
However, the use of any psychoactive substance in this age 
group is of concern as the brain and other organs are still 
developing during adolescence, and exposure to toxic 
substances may cause damage, though it might only appear 
later in life. In addition, early initiation during adolescence 
has been associated with higher probability of drug use 
later in life and greater difficulties in reducing or ceasing 
drug use (von Sydow et al., 2002). Polydrug use among 
adolescents, defined as the use of at least two different 
psychoactive substances at a young age, could be 
considered an indirect indicator for early initiation. 
Furthermore, the use of illicit substances that are uncommon 
at this age — depending on the local context these might be 
cannabis or other drugs such as cocaine — could also 
reflect higher levels of risk behaviours, social exclusion or 
deviance among adolescents.
In this report, individual data from the surveys carried out in 
2003 by the European school survey project on alcohol and 
other drugs (ESPAD) are used to examine the characteristics 
of polydrug use among over 70 000 15- to 16-year-old 
students from 22 European countries (1). In order to attain 
sufficiently large samples for statistical analysis, while also 
allowing exploration of differences in polydrug use patterns 
in different contexts, the countries were divided into three 
distinct groups based on their prevalence levels of substance 
use during the last 30 days (last month use) (2)..The countries 
assigned to the low-prevalence group were Greece, Cyprus, 
Malta, Romania, Finland, Sweden, Turkey and Norway. The 
medium-prevalence group was made up of Bulgaria, Latvia, 
Lithuania, Hungary, Slovakia, Slovenia and Croatia, and the 
high-prevalence group consisted of Belgium, the Czech 
Republic, Denmark, Germany, Estonia, the Netherlands and 
the United Kingdom.
Last month prevalence of drug use among school students in 
Europe (see Table 1) is dominated by the consumption of 
alcohol and cigarettes, with cannabis following in third 
place. The use of other illicit drugs during the last month 
seldom exceeds 1 % of the school student population. 
Research also indicates that adolescent drug use tends to 
occur during short periods, such as an evening out or over a 
weekend (Collins et al., 1998).
(1) Details of the data analysis are published in Olszewski et al. (2009). 
(2)  Hierarchical cluster analysis was performed using Ward’s method. Drug use prevalence in each country for each of five drugs (cigarettes, cannabis, 
cocaine, ecstasy and amphetamines) and for alcohol binge drinking (drinking five or more drinks in a row), was scaled to lie between 0 and 1 by using the 
minimum and maximum for all participating countries (see Figure A1 in the online annex).
Why do people use multiple drugs?
There are different rationales for mixing different drugs 
during one consumption episode. Drugs, which when taken 
together can have cumulative or complementary effects, 
may be mixed to increase the overall psychoactive 
experience. Offsetting the negative effects of a drug can 
be another reason to take an additional substance; for 
example, benzodiazepines to help the user sleep after 
taking stimulants. 
The use of several substances by an individual over a 
longer period of time might reflect the replacement of one 
drug by another, due to changes in price, availability, 
legality or fashion (Boys et al., 1999). Examples are 
cocaine replacing ecstasy, methadone substituting heroin, 
or gamma-butyrolactone (GBL) replacing gamma-
hydroxybutyric acid (GHB) after GHB came under drug 
law control. It could also reflect the use of separate drugs in 
different settings or contexts, or simply reflect regular 
multi-substance use associated with drug dependence.
Overall, the types of psychoactive substances that are used 
in combination depends not only on personal preferences, 
but also on other factors such as local availability and 
fashion, and for prescribed psychoactive medicines, on 
local prescribing practices (Gossop et al., 1998). Increases 
in the range of drugs available are usually accompanied 
by more polydrug use, as well as by increases in the social 
acceptability of combining various psychoactive substances 
(Ives and Ghelani, 2006).
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Types of adolescent polydrug user
Around 30 % of the 15- to 16-year-old students of the 22 
countries included in the analysis reported having 
consumed two or more substances in the month before 
taking part in the survey. The proportion of polydrug users 
was nearly 40 % in the high-prevalence country group, 
36 % in the medium-prevalence country group and 22.5 % 
in the low-prevalence group. Some 91 different drug 
combinations were reported, possibly reflecting national 
differences in drug markets and lifestyles. However, more 
than 96 % of the students who reported having used two or 
more substances could be placed in one of three types of 
polydrug users: 
•  A type — alcohol and cigarettes;
•  B type — cannabis together with alcohol and/or 
cigarettes; 
•  C type — cannabis together with alcohol and/or 
cigarettes and at least one of the following: ecstasy, 
cocaine, amphetamines, LSD or heroin.
Just over 20 % of the school students in the entire database 
reported the use of both alcohol and cigarettes (A type) 
during the previous month, 6 % reported the use of cannabis 
and alcohol and/or cigarettes (B type) and 1 % reported in 
addition the use of ecstasy, cocaine, amphetamines, LSD or 
heroin (C type). 
Almost three-quarters (73 %) of all last month polydrug-using 
school students mentioned the use of both alcohol and 
cigarettes, but no use of an illicit drug (see Table 2). 
One-fifth reported the use of cannabis and alcohol and/or 
cigarettes, and 3.5 % reported, in addition, the use of 
ecstasy, cocaine, amphetamines, LSD or heroin. As 
expected, the proportion of those using illicit drugs (B and C 
types) among polydrug users is much larger in the country 
cluster of high prevalence of drug use (39.5 %) than in the 
medium (21.1 %) and low (9.4 %) prevalence clusters. Some 
gender differences can be detected in the patterns of 
polydrug use among school students. While among those 
reporting type A polydrug use girls slightly outnumber boys, 
boys are overrepresented among type C polydrug users. 
Table 1: Range of last month prevalence of substance use among 15- to 16-year-old school students in 
22 European countries and average prevalence by cluster
Substance
Prevalence range (%),  
all countries
Average prevalence (%)
Low-prevalence 
countries 
Medium-prevalence 
countries 
High-prevalence 
countries 
Alcohol 20–81 50.8 65.3 73.1
Binge alcohol (1) 15–60 34.6 38.4 51.8
Cigarettes 18–46 26.7 40.5 36.3
Cannabis 0–20 2.2 7.6 15.0
Ecstasy 0–3 0.5 0.8 1.3
Hallucinogenic mushrooms 0–2 0.3 0.3 0.8
LSD or other hallucinogens 0–1 0.3 0.3 0.6
Amphetamine 0–1 0.4 0.8 0.9
Cocaine 0–1 0.4 0.3 0.6
Heroin 0–1 0.3 0.2 0.3
(1) Binge alcohol is defined as drinking five or more drinks in a row.
NB: Data for 19 EU Member States together with Norway, Croatia and Turkey (n = 76 541).
Source: ESPAD 2003.
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School students who reported using cannabis in the last 
month rarely reported using other illicit substances during 
that time. This may be expected, as first use of illicit 
substances other than cannabis generally occurs at a later 
age. However, among those who reported using cocaine, 
use of other illicit drugs was much higher. This finding should 
be interpreted with caution given the low number of cocaine 
users in this age group, but it points to the existence of a 
small segment of the school population already engaged in 
high-risk behaviour. The prevalence of binge drinking 
among school students who have used cocaine reached 
94 % in some countries, a figure that raises concern in view 
of the health risk to the individuals who combine cocaine 
use with binge drinking (Leccese et al., 2000).
Table 2: Type of substance combinations among 15- to 16-year-old school students who reported last 
month polydrug use, in each of the clusters of low-, medium- and high-prevalence countries 
Country group Type A (%) Type B (%) Type C (%) Other (%) n
Low-prevalence 85.3 7.5 1.9 5.3 5 758
Medium-prevalence 76.3 17.9 3.2 2.6 8 496
High-prevalence 57.5 34.4 5.1 3.0 7 522
All countries 73.0 20.0 3.5 3.5 21 776
NB:  Typology of polydrug use: type A, alcohol and cigarettes; type B, cannabis in addition to alcohol and/or cigarettes; type C, type B plus at least 
one of the following: ecstasy, cocaine, amphetamines, LSD or heroin. 
Data for 19 EU Member States together with Norway, Croatia and Turkey (n = 76 541).
Source: ESPAD 2003.
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Figure 1: Use of selected illicit drugs during the last month among cannabis users and among all 15- to 16-year-old school students in the 
clusters of low-, medium- and high-prevalence countries
NB: Data for 19 EU Member States together with Norway, Croatia and Turkey.
Source: ESPAD 2003.
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The overall proportion of school students using at least two 
illicit drugs is low but, as expected, is greater in the high-
prevalence countries compared to the others. However, 
pairwise associations between the use of two different illicit 
drugs show another important aspect of the phenomenon 
(Table 3) — cannabis and cocaine users in countries with 
low overall prevalence levels of drug use have a higher risk 
of taking other illicit drugs, in comparison with the general 
student population, than their counterparts in high-
prevalence countries. This reflects the normalisation (3) of 
cannabis use in high-prevalence countries and the fact that 
the use of illicit substances, including cannabis, in low-
prevalence countries is more frequently associated with 
deviant behaviours. In high-prevalence countries, cannabis 
users reported levels of use for other illicit drugs that were 
around five times those in the general school population of 
15- to 16-year-olds, while in low-prevalence countries the 
ratio was about twenty times (Figure 1). In low-prevalence 
countries, cocaine users were more than 100 times more 
likely to use illicit drugs other than cannabis than were 
students in the school population as a whole.
An association between the use of licit and illicit substances 
is illustrated by the fact that students who used cannabis had 
prevalence estimates for cigarette smoking that were 
between two and three times higher than in the general 
school student population; and the pattern hardly varied 
between low, medium and high-prevalence countries. It is 
also worth noting that, in general, school students who 
reported binge drinking or smoking cigarettes were around 
twice as likely to smoke cannabis as students in the general 
school population.
(3) A situation in which ‘mainstream youth culture assimilated and legitimated recreational drug use’ (Parker et al., 1998, p. 151).
Table 3: Last month use of other illicit drugs among cannabis and cocaine users, and comparison  
(rate ratios) with all 15- to 16-year-old school students in each of the clusters of low-,  
medium- and high-prevalence countries
Cannabis users 
Average prevalence of 
use (all countries) (%)
Rate ratio (1)
Low-prevalence 
countries (n = 562)
Medium-prevalence 
countries (n = 1 795)
High-prevalence 
countries (n = 2 982)
Ecstasy ** 9.4 25.6 9.5 6.0
Cocaine ** 5.6 28.0 8.3 5.3
Hallucinogenic mushrooms 5.9 33.6 9.3 6.9
Amphetamines ** 6.8 22.8 8.3 4.7
Heroin * 4.1 29.0 11.0 5.0
LSD 4.2 23.3 9.3 6.3
Cocaine users 
Average prevalence of 
use (all countries) (%)
Low-prevalence 
countries (n = 103)
Medium-prevalence 
countries (n = 66)
High-prevalence 
countries (n = 109)
Cannabis ** 65.1 25.6 8.8 5.1
Ecstasy ** 53.6 136.6 51.9 39.2
Hallucinogenic mushrooms ** 35.3 195.7 70.7 37.0
Amphetamines ** 35.6 139.8 37.9 20.7
Heroin * 40.7 220.0 177.0 69.0
LSD ** 35.0 190.0 92.3 34.0
(1)  Rate ratio: relationship between prevalence in two population groups (cannabis or cocaine users compared to the general population as the 
reference category) expressed as the quotient of one divided by the other. A rate ratio of 25 means that a cannabis (or cocaine) user is 25 times 
more likely to have used a given substance than a member of the general school population in a given cluster.
NB:  Data for 19 EU Member States together with Norway, Croatia and Turkey (n = 76 541).
 Statistically significant differences in rate ratios between low-, medium- and high-prevalence countries are denoted by asterisks: * P < 0.001, 
 ** P < 0.0005. 
Source: ESPAD 2003.
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Social factors associated with polydrug use
Three social factors (lack of parental control, truancy from 
school and perceived family affluence) were explored for 
their association with type C polydrug use (which includes 
the use of cannabis and at least one other illicit drug) and 
for differences between country clusters. Between 22 % and 
32 % of type C polydrug users in all the countries reported 
that their parents usually did not know where they were in 
the evenings; but the strongest association was found in 
low-prevalence countries. The same could be observed with 
regard to school truancy (skipping school three or more 
times during the last month); almost half of the type C 
polydrug users in low-prevalence countries truanted from 
school, compared to only one-fifth in the high-prevalence 
countries (Figure 2). In terms of family affluence, type C 
polydrug users in high-prevalence countries are more similar 
to the general school population than are type C polydrug 
users in the other clusters, illustrating again that drug use has 
been normalised in high-prevalence countries.




-PX .FEJVN )JHI

5ZQF" 5ZQF# 5ZQF$
Figure 2: Proportion of polydrug users truanting from school  
(three or more times in the last month) by type of substance 
combinations and clusters of low-, medium- and high-prevalence 
countries
NB:  Typology of polydrug use: type A, alcohol and cigarettes; type B, 
cannabis in addition to alcohol and/or cigarettes; type C, type B 
plus at least one of the following: ecstasy, cocaine, amphetamines, 
LSD or heroin.
Source: ESPAD 2003.
Polydrug use among young adults 
While polydrug use among adolescents can be an indicator 
of early initiation, risk behaviours or deviance, polydrug use 
among young adults can be symptomatic of more 
established patterns of multiple substance use, potentially 
carrying long-term health problems and acute risk during 
leisure time. Polydrug use among problem drug users — 
those showing frequent and often long-term use of the most 
harmful illicit substances — is specifically addressed 
elsewhere in this report.
Data on young adults (15–34 years) has been drawn from 
general population surveys conducted between 2005 and 
2008 in nine EU Member States. Full access to individual 
data was not possible, therefore data analysis was based 
on conditional associations between the use of different 
substances. This allowed us to explore if the use of one 
substance by an individual increased the likelihood of using 
another one. The sample sizes of young adults in the surveys 
ranged from 1 753 to over 10 000 individuals, and 
because there was relatively little data for last month drug 
users the analysis was extended to those reporting having 
used drugs during the last year. 
Alcohol use and cigarette smoking, followed by cannabis 
use, were the most prevalent forms of substance use 
consistently reported by young adults in all countries. 
However, there were wide variations among the nine 
reporting countries: the prevalence of cannabis use in the 
last year ranged from 3.6 % to 20.9 % and last year 
cocaine use ranged from 0.9 % to 5.1 % (Table 4).
Among young adults (aged 15 to 34), frequent or heavy 
alcohol users were, in general, between two and six times 
more likely to report the use of cannabis compared to the 
general population and between two and nine times more 
likely to use cocaine. The strongest associations between 
heavy alcohol and illicit drug use were found in the 
countries with the lowest prevalence of heavy alcohol use 
(Cyprus, France, Italy, Portugal), and the weakest 
associations in those countries where frequent or heavy 
alcohol use is more widespread, such as Ireland and the 
United Kingdom (England and Wales). In France, the 
prevalence of cocaine use among frequent or heavy alcohol 
drinkers was 8 %, compared with just over 1 % in the 
general population, and in Italy the corresponding figures 
were 27 % and 3 % (Figure 3).
Most cannabis users did not report the use of other illicit 
drugs, but they were nevertheless more likely to do so than 
the general population (Figure 4). The prevalence of last 
year use of other illicit drugs among cannabis users varied 
between 4 % (Italy) and 35 % (Cyprus) for ecstasy; between 
1 % (France) and 17 % (Denmark) for amphetamines; and 
between 6 % (France) and more than 20 % (Cyprus, Ireland, 
Spain and the United Kingdom) for cocaine. Overall, 
cannabis users were between 4 and 25 times more likely to 
report the use of cocaine than were the general population. 
The strongest associations between the use of cannabis and 
cocaine were found in four countries with relatively low 
cannabis use prevalence (Cyprus, Germany, Ireland, 
Portugal).
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Table 4: Prevalence of frequent or heavy alcohol use and last year prevalence of cannabis and 
cocaine use among young adults (15–34)
Country Survey date 
Frequent or heavy 
alcohol (1) (%)
Cannabis (%) Cocaine (%) Sample size
Ireland 2006/07 30.3 10.4 2.9 1 989
Denmark 2008 18.6 13.3 3.4 1 744
United Kingdom (2) 2007/08 9.9 15.4 5.0 7 176
Germany 2006 9.2 12.0 1.5 3 306
Spain 2007/08 7.6 19.6 5.1 9 443
Cyprus 2006 5.9 3.6 0.9 1 753
France 2005 5.3 16.7 1.2 10 855
Portugal 2007 2.0 6.7 1.2 4 765
Italy 2007 1.8 20.9 3.1 4 243
(1)  Defined by the EMCDDA as drinking six glasses or more of an alcoholic drink on the same occasion at least once a week during the past 12 
months. The United Kingdom and Spain use other definitions, and comparisons should therefore be made with caution.
(2) England and Wales, the age range is 16–30. 
Source: National experts for general population surveys of participating countries. 





*UBMZ 4QBJO 'SBODF %FONBSL 1PSUVHBM 6OJUFE
,JOHEPN	

(FSNBOZ *SFMBOE $ZQSVT

$BOOBCJTVTFBNPOH
GSFRVFOUBMDPIPMVTFST
HFOFSBMQPQVMBUJPO
$PDBJOFVTFBNPOH
GSFRVFOUBMDPIPMVTFST
HFOFSBMQPQVMBUJPO
Figure 3: Frequent or heavy alcohol users (1) — use of cannabis and cocaine during the last 12 months compared to the general 
population of 15- to 34-year-olds
(1)  Defined by the EMCDDA as drinking six glasses or more of an alcoholic drink on the same occasion at least once a week during the past 12 months. 
The United Kingdom and Spain use other definitions, and comparisons should therefore be made with caution.  
(2)  England and Wales, the age range is 16–30.
Source: National experts for general population surveys of participating countries.
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Many of the young adults who reported using cocaine in the 
last year also reported using other drugs during same 
period. The prevalence of use of other drugs was much 
higher among cocaine users than among cannabis users, 
although caution is required when interpreting data from 
countries with relatively small numbers of users. In all 
countries, the majority of cocaine users (67–89 %) have also 
used cannabis. Cocaine users also reported higher levels of 
use of other stimulants (amphetamines and ecstasy) 
compared to cannabis users, but with important country 
differences. For example, more than 60 % of young adults 
reporting last year cocaine use in Denmark and Germany 
also reported use of amphetamine; use of ecstasy was 
reported by more than 50 % of young cocaine users in 
Cyprus, Ireland and the United Kingdom (England and 
Wales); while not more than 31 % of young cocaine users in 
Italy and Portugal reported the use of either of these two 
substances (4). Cocaine users also reported high levels of 
frequent or heavy drinking (14–58 %). And, although the 
lowest levels of frequent or heavy drinking among cocaine 
users were reported for Italy and Portugal, these levels are 
particularly high when compared with the general 
population of these two countries, where only 2 % reported 
frequent or heavy drinking. In Ireland, the prevalence of this 
form of alcohol use among cocaine users was only twice 
that among the general population (30 %). 
Polydrug use in recreational settings 
Young people are exposed to a dynamic and expanding 
drugs market, with an increasing range of (licit and illicit) 
psychoactive substances or products being made easily and 
cheaply available. The expansion of the leisure and alcohol 
industry into areas of youth culture has also meant that, in 
many European countries, there is now a critical mass of 
potential polydrug users who regularly gather in large 
numbers at music clubs and other nightlife settings (Calafat 
et al., 2003; Bellis et al., 2002). New technologies have 
also facilitated communication about drugs, their effects, 
where and how to get them, within and between social 
networks. 
Polydrug use often takes place in the context of recreational 
activities, with population surveys confirming that drug use is 
associated with visiting bars and nightclubs. Studies 
conducted in targeted nightlife settings during the past 
(4) See Table A1 in the online annex.
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Figure 4: Cannabis users — frequent or heavy alcohol use (1) and cocaine use during the last year compared to the general population of 
15- to 34-year-olds
(1)  Defined by the EMCDDA as drinking six glasses or more of an alcoholic drink on the same occasion at least once a week during the past 12 months. 
The United Kingdom and Spain use other definitions, and comparisons should therefore be made with caution.  
(2) England and Wales, the age range is 16–30.
Source: National experts for general population surveys of participating countries.
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decade in several Member States have found comparatively 
high levels of drug use.  
Studies conducted in recreational settings in 2007 are 
available from five countries (Belgium, Czech Republic, 
Latvia, Lithuania, Austria). Lifetime prevalence estimates in 
these studies ranged from 15 % to 71 % for ecstasy use and 
from 17 % to 68 % for amphetamine use. The Czech 
Republic also reported recently a rise in the acceptability 
and attractiveness of cocaine and ecstasy use. 
A study conducted in 2006 among a sample of 1 383 
young people in nightlife settings in nine European cities 
(Athens, Berlin, Brno, Lisbon, Liverpool, Ljubljana, Palma, 
Venice, Vienna) found that the frequent use of individual 
drugs varies between cities and appears to reflect the 
prevalence levels among the general population and the 
availability of the substances. Tobacco (48 %), alcohol 
(11 %) and cannabis (9 %) were overall the substances 
most commonly used on a regular basis (five or more days 
a week); fewer than 1 % of respondents reported regular 
use of other substances. However, the study identified the 
existence of a very small group of drug users who 
consumed drugs in an extremely intensive manner. It also 
found that concomitant alcohol use was common, with 
34 % of those interviewed reported having been drunk 
more than twice during the four weeks before the 
interview. Drunkenness is likely to increase the risk of 
making ill-considered decisions about drug taking, and 
was more commonly reported by males than females: 
42 % and 27 % respectively (European Commission, 
2007).
Two recently conducted studies in recreational settings were 
reported by Belgium. The first one, in the Flemish 
Community, surveyed over 2 000 people in three clubs 
during different events held in 2003, 2005 and 2007. The 
study found that almost half of those who reported the use of 
an illicit drug during the last year stated that they regularly 
combined alcohol and an illicit drug, and one in four drug 
users regularly combined different illicit drugs. Cannabis 
and cocaine were used both before and after going out. The 
second study, in the French Community, surveyed 2 444 
individuals during music festivals in 2007 and found that 
68 % of respondents used at least one psychoactive 
substance during such an event (tobacco not included). 
Some 38 % used only one substance, while 18 % used two 
substances and 12 % used three or more during the event. 
Among those who had used alcohol or drugs during the 
event (n = 1 649), the most common combination was 
alcohol and cannabis (19 %). Ecstasy users took an average 
of three other products (n = 165) and cocaine users an 
average of four other products (n = 86).  
In the context of recreational drug taking, polydrug use can 
be time-limited and linked to a specific social situation or 
location. For example, one finding from a 2002 drugs survey 
conducted among 868 tourists at Ibiza airport is that those 
who were already using drugs in the United Kingdom had a 
significantly higher frequency of use during the holiday 
period. Some 6.7 % reported using ecstasy for five nights or 
more while in the United Kingdom, compared with 36.9 % 
while in Ibiza; on average consumers used at least two illicit 
drugs during the holiday (for example, 46 % of ecstasy users 
also used cocaine) as well as alcohol (Bellis et al., 2003). 
Furthermore, some individuals who had never used illicit 
drugs at home started using while on holiday in Ibiza. An 
EMCDDA ‘Selected issue’ on recreational drug use reported 
that Swedish research found that 23 % of the young people 
surveyed had tried illicit drugs for the first time while abroad, 
and in Spain recreational drug use was reported to be 
highest among concentrations of young people on the 
Mediterranean coast where there are many tourists 
(EMCDDA, 2006). Evidence suggests that during short 
holiday periods and weekends, young people are particularly 
liable to indulge in drug-related activities that put them at risk, 
which highlights the need for specifically targeted prevention 
and harm-reduction responses that take into account the 
context in which polydrug use occurs (Bellis et al., 2003). 
Responses to polydrug use among 
adolescents and young adults
Data, both for adolescents and young adults, suggest that 
there is, in all countries, a limited group of people that 
consume multiple licit and illicit drugs, sometimes with a high 
frequency of use. Among adolescents, the use of several 
substances, including at least two illicit drugs, appears to be 
generally correlated with truancy and family risk factors. 
However, in countries where prevalence of drug use is 
highest, this correlation is weaker because non-vulnerable 
adolescents are also likely to use drugs such as cannabis. In 
these countries, a large number of non-vulnerable and 
lower-risk substance users may contribute to a greater share 
of health problems than the smaller number of vulnerable 
drug users who are individually at much greater risk. This is 
known as the ‘prevention paradox’ (Spurling and Vinson, 
2005). In these countries, prevention strategies should 
address the norms and behaviours of non-vulnerable 
substance users, while also including selective measures 
targeting the most vulnerable and at-risk ones. In contrast, in 
countries where prevalence of alcohol and drug use is low, 
a larger proportion of health and social problems may occur 
among vulnerable or marginalised people consuming drugs, 
and these can be reached with selective and indicated 
prevention interventions.
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Responses to widespread use of alcohol, 
cigarettes and cannabis use among young 
Europeans: environmental approaches 
There is evidence that alcohol and tobacco policies that 
target the market environment, such as pricing, taxation, 
regulating locations for sale and consumption of alcohol, 
including happy hour restrictions, have an impact on the use 
of these substances and the related health consequences 
(Toumbourou et al., 2007). Prevention strategies can also 
attempt to alter the cultural, social and physical 
environments in which people make their choices about drug 
use. The environmental approach acknowledges that 
individuals are influenced by a complex set of factors, such 
as social norms, regulations, mass media messages and 
accessibility of alcohol, tobacco or illicit drugs. Within this 
framework, tobacco and alcohol (and more recently 
cannabis) are viewed as industrial epidemics (Jahiel and 
Babor, 2007) that require modification of the social norms 
and market regulation.
Current developments in environmental strategies include 
the introduction of full smoking bans in all public places 
and workplaces (including restaurants and bars) by 12 EU 
Member States. Belgium, Spain, Denmark, Germany and 
Portugal have also introduced partial smoking bans. Other 
interventions include proposals for a code of conduct for 
alcohol advertising; integration of roadside drug screening 
alongside drink driving tests; and EU-wide indexation of 
existing minimum excise duties on alcohol. These strategies 
may have a knock-on effect on cannabis consumption and 
other illicit drug use. For example, studies have suggested 
that cannabis use may perpetuate cigarette smoking 
(Amos et al., 2003), and it is possible that tobacco 
policies and EU-wide tobacco advertising bans have 
influenced the prevalence of cannabis use as well as that 
of cigarette smoking. A study by Farrelly et al. (2001) also 
suggests that increases in cigarette taxation can reduce 
the intensity of cannabis use and may have a modest 
effect on the probability of use among males. Smoking 
bans and tax increases tend, however, to show direct 
effects on adults and indirect effects — possibly mediated 
through social norms — on adolescents (Aspect 
Consortium, 2004). 
Structural national prevention measures targeting the 
availability of cannabis are rare. However, the Dutch 
government has now ruled that, in addition to other existing 
regulatory measures, coffee shops should not be located in 
the immediate vicinity of schools, and this could lead to a 
reduction in the overall number of retail outlets. Public 
smoking of cannabis has also become subject to a fine in 
the city of Amsterdam.
Perceptions of cannabis, particularly those of adolescents, 
are modulated more by personal experiences, observation 
of others and beliefs than by receiving objective information 
about the risks related to cannabis use (Springer et al., 
1996). Normative beliefs are considered particularly 
important for young people who use cannabis, as they tend 
to view the prevalence of use among their immediate peers 
as being ‘normal’, and may thereby overestimate the overall 
prevalence of cannabis use in the population (Page and 
Roland, 2004). Some Member States have reported 
attempts to reverse the social perception of cannabis use as 
being a ‘normal’ behaviour, and to correct misconceptions 
that a majority of young people use drugs (EMCDDA, 
2004). Cannabis use is also associated with specific youth 
subcultures, and some prevention programmes focus on 
deconstructing or neutralising certain ‘market images’ of 
cannabis, but these programmes still need to be evaluated 
for their effectiveness.
Environmental approaches in schools can take the form of 
structural and regulatory policies and practices — school 
rules. And, these measures may have an impact on 
preventing or delaying licit and illicit substance use (Hawks 
et al., 2002). The majority of Member States report that 
most of their schools have drug and alcohol polices that 
define procedures and rules about use and possession of 
licit and illicit substances in and around the school premises. 
Prevention responses targeting vulnerable young 
people
Selective prevention usually targets vulnerable groups who 
share common socio-demographics and intervention needs, 
which are mostly related to social exclusion and increase the 
risk of developing problem drug use. Prevention strategies 
that specifically target polydrug use among the most socially 
vulnerable populations, especially those with social or 
academic problems, and young people who live in 
disadvantaged families or neighbourhoods where multiple 
risk factors are concentrated, are described in the ‘Selected 
issue’, Drugs and vulnerable groups of young people 
(EMCDDA, 2008b). 
Indicated prevention focuses on diagnosed persons with an 
individually attributable vulnerability that increases their 
propensity to develop drug problems. Fast trajectories into 
problem drug use due to individual vulnerability factors, 
such as sensation seeking, impulsivity, aggressiveness and 
mental health problems, are extensively discussed, along 
with the corresponding prevention interventions, in a recent 
EMCDDA ‘Thematic paper’ on indicated prevention 
(EMCDDA, 2009b). As both selective and indicated 
prevention strategies target underlying vulnerability at social 
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(selective prevention) or individual (indicated prevention) 
level, rather than the use of specific drugs, they are suitable 
for addressing polydrug use.
Responses targeted at drug users in recreational 
settings
The high prevalence of polydrug use found in certain 
recreational settings, such as clubs, festivals or raves, 
identifies them as important environments for implementing 
prevention and harm-reduction measures. The responses to 
drug use in these settings that are most frequently reported 
by EU Member States are targeted information campaigns, 
which often rely on the dissemination of information through 
flyers, booklets and the Internet. These materials are usually 
designed to reflect youth culture and are distributed through 
outreach mobile prevention teams. They aim to raise 
awareness of the potential health risks associated with 
commonly consumed substances, including alcohol, as well 
as the consequences of mixing substances. The Belgian 
Partywise website, for example, allows users to select two 
substances and read about the potential health 
consequences of using them in combination (5). 
Guidelines for club owners about minimum health and safety 
standards in recreational settings, such as the ‘Safer 
dancing’ guidelines in the United Kingdom, are another 
intervention developed to prevent the acute health risks that 
are associated with the single or combined use of licit and 
illicit substances. While 12 countries now report that such 
guidelines have been developed for nightlife venues, only 
the Netherlands, Slovenia, Sweden and the United Kingdom 
report that they are monitored and enforced. The guidelines 
generally include measures such as overcrowding control, 
provision of free and accessible water, immediate 
availability of first aid by trained staff, chill-out rooms or 
provision of information material on the prevention and 
reduction of harm associated with drugs usually consumed 
in nightclubs. In a recent EMCDDA survey, national experts 
from most reporting EU Member States reported that these 
measures were available in fewer than half of the nightclubs 
with sufficiently large target populations for the intervention 
to be implemented (Figure 5). Worryingly, several national 
experts reported that free accessible water is rarely or not 
available in nightclubs. The purchase of alcoholic drinks 
might then be favoured over the purchase of water and this 
might increase the risk of negative health consequences.
(5) http://www.partywise.be/page2.htm
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Figure 5: Availability of measures to reduce substance-related health risks and improve the overall safety of partygoers in nightclubs
NB:  Availability is defined by the provision of the specified measure in nightclubs with sufficiently large target populations for the intervention to be 
implemented: nearly all (full); the majority, but not nearly all (extensive); more than a few, but not the majority (limited); only a few (rare); not 
available. Information was collected by means of a structured questionnaire.
Sources: Reitox national focal points.
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Other strategies attempt to alter the social, economic and 
physical environment associated with alcohol and drug 
consumption. The aims of these strategies include modifying 
consumption behaviours and norms, creating conditions less 
favourable to intoxication and injuries, and reducing the 
opportunities for substance-related problems to occur (6). 
Measures reported by Member States that take place in or 
around nightlife settings include: training for bar and security 
staff, for example, to refuse entrance to intoxicated or 
aggressive customers; enforcement of existing drug and 
alcohol legislation; distribution of leaflets and posters to raise 
awareness of substance-related harms; provision of late-night 
transport services; provision of lighting and ventilation suitable 
for a safe nightlife environment. The implementation of such 
measures is often based upon dialogue and partnership 
between different stakeholders, such as the police, licensing 
authorities, club owners and healthcare providers. 
Strategies that address the environment in which young 
people consume drugs and alcohol appear to have 
considerable potential for safeguarding public health and 
improving public safety, with benefits that can extend into 
the wider community (Bellis et al., 2002; World Health 
Organization, 1997). However, full implementation tends to 
be limited to particular, known problem areas and to a few 
Member States. In addition, acknowledgment that alcohol is 
a main contributor to substance-related harm in recreational 
settings is often limited and, in most Member States, 
responses to illicit drugs are addressed separately from 
alcohol. Non-governmental organisations working in 
prevention and harm reduction in recreational settings have 
little or no influence on environmental alcohol policies. For 
all these reasons, there is considerable potential for 
improving the responses to polydrug use in nightlife settings. 
Polydrug use and its health consequences 
among problem drug users
Problem drug users (7), those practising the more intensive 
and damaging forms of drug use, often suffer from 
underlying health problems, which can increase their 
susceptibility to the harmful effects of combining drugs. 
Furthermore, some of the drug combinations commonly 
taken by problem drug users are associated with particularly 
elevated risks. These risks and health consequences are 
examined below, with particular attention to clients in opioid 
substitution treatment, among whom polydrug use levels are 
very high, and are connected with severe adverse health 
and psychosocial consequences. 
Acute health problems and drug-induced deaths 
related to polydrug use
Interactions between different drugs consumed close 
together in time can lead to increased toxicity. This can 
occur due to additive or potentialising effects, 
pharmacokinetic factors (e.g. reduced metabolism leading 
to higher blood concentrations), or to other interactions, 
such as the production of a new metabolite derived from the 
drugs or their breakdown products. The effects of certain 
psychoactive substances can also lead to increased risk 
behaviour with another substance. For instance, alcohol 
intoxication can reduce the capacity to judge the amount of 
opioids consumed or reduce awareness of the loss of 
tolerance to opioids that is likely to occur after discharge 
from treatment or release from prison. The co-use of several 
substances can also increase the risk of negative outcomes, 
such as accidents or injuries. Research has also shown that 
the added effects of multiple substance use can increase 
considerably the risk of road accidents, even with relatively 
low levels of intoxication (EMCDDA, 2007). 
Hospital emergency services report that polydrug 
intoxications, with alcohol playing a key role, represent a 
significant proportion of medical emergencies (Sopenã et 
al., 2008). Cardiologists also report that cocaine users 
typically consume other toxic substances (including tobacco), 
resulting in greater diagnostic difficulties. It is suggested that 
cocaine use be considered when young adults present with 
chest pain (Guiraudet et al., 2001).
The true numbers of drug-induced deaths (8) in Europe, as 
well as the extent to which these are caused by the 
consumption of more than one substance, is likely to be 
underestimated for a number of reasons. Therefore, a pilot 
study was carried out to explore the feasibility of collecting 
further information on the substances involved in the drug-
induced deaths reported to the EMCDDA, drawing on 
general and special mortality registries. Nine countries (9) 
reported more than 6 900 deaths (two-thirds of which were in 
(6) http://www.emcdda.europa.eu/themes/prevention/environmental-strategies
(7) The EMCDDA defines ‘problem drug use’ as ‘injecting drug use or long-duration/regular use of opioids, cocaine and/or amphetamines’.
(8)  Also known as overdose deaths or poisonings. For more information on the EMCDDA drug-related deaths protocol and definitions see http://www.
emcdda.europa.eu/themes/key-indicators/drd.
(9) Czech Republic, Denmark, Germany, Latvia, Malta, Netherlands, Austria, Portugal, United Kingdom.
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the United Kingdom) that had occurred between 2002 and 
2005. The reporting countries generally used the sources of 
information and case definitions recommended by the 
EMCDDA (10). The substances searched for and reported 
included opioids, cocaine, amphetamines, hallucinogens, 
cannabis, volatile substances, psychoactive medicines and 
alcohol. Some countries also reported that certain substances 
were less likely to be searched for or reported (e.g. cannabis). 
The results of this feasibility study are in line with the data 
collected through the EMCDDA drug-related death indicator 
and show that the vast majority of reported drug-induced 
deaths are related to opioids. At least one opioid was found 
in the post mortem toxicology of three-quarter of all cases 
(77 %), followed by cocaine which was found in one-fifth of 
cases (21 %), and amphetamines (7 %). 
The pilot study provided preliminary evidence of the high 
proportion of drug-induced deaths in which more than one 
psychoactive substance was detected. Overall, an opioid 
was detected as the sole substance in 18 % of the deaths, 
and together with alcohol in an additional 13 %. Cocaine 
was detected as the sole substance in 3 % of the deaths, 
and in combination with opioids in a further 8 %. Other 
combinations of drugs, most of which included opioids, were 
found in the remaining deaths. 
Methadone was detected in about one-fifth (19 %) of the 
drug-induced deaths examined. Of these, it was mentioned 
as the sole drug in only 12 % of cases in combination with 
alcohol in a further 8 % and with another opioid in another 
10 %. In the remaining cases, methadone was associated 
with other psychoactive substances. 
Although these are preliminary results and there are some 
methodological limitations, the data from this feasibility study 
confirm that opioid use constitutes, by far, the most frequent 
background against which drug-induced deaths occur. These 
deaths are frequently related to combinations of substances, 
and only a minority of cases are related to one substance 
only. This might reflect the prevalence of polydrug use among 
drug users, as well as the increased risk of overdose and 
adverse effects when substances are combined. 
As some substances may not have been identified or 
reported, the involvement of drug combinations in the deaths 
examined in the feasibility study may be underestimated. 
The presence of alcohol and psychoactive medicines could 
not be measured fully with the data collected, but figures are 
thought to be very high. The EMCDDA is developing the 
monitoring of polydrug use and particularly wants to 
improve measurement of the fraction of drug-induced deaths 
in which alcohol and psychoactive medicines, particularly 
benzodiazepines, played a role. Polydrug use, particularly 
its fatal consequences, should be explored further to inform 
public health interventions.
In addition to drug-induced deaths, non-fatal overdoses 
constitute a major public health problem, which can be 
aggravated by polydrug use. Studies suggest that among 
heroin users the most common cause of non-fatal overdose, 
besides taking a higher dose and taking heroin with 
increased purity levels, is using alcohol at the same time as 
heroin (Gossop et al., 1996). 
Chronic risks and problems linked to ongoing 
polydrug use
Longitudinal cohort studies that follow problem drug users in 
Europe (e.g. opioid or cocaine users, or injectors) over long 
periods of time show a very high mortality rate, compared 
to the general population, due to causes such as overdoses, 
diseases and violence (Bargagli et al., 2005; Clausen et al., 
2009). These studies include mainly opioid users, most of 
whom are polydrug users (including tobacco and alcohol) 
and present other social and personal risk factors. Overdose 
deaths will often be the result of, or occur against a 
background of, polydrug use, combined with the effects of 
chronic alcohol use (e.g. hepatic disease) or tobacco use 
(respiratory diseases). Other diseases leading to increased 
mortality can be influenced by chronic combined use of 
alcohol, tobacco, cocaine and other substances (Cruts et al., 
2008). Overall, continued use of several substances can 
lead to longer-term toxicities in various organs or body 
systems (e.g. liver, cardiovascular, neurological).
Another dimension of chronic health damage, related to the 
use of different substances, is the aggravating effect of 
heavy alcohol use in the prognosis of liver disease due to 
chronic hepatitis C infection acquired through previous drug 
injection (11). Studies also report a very high prevalence of 
tobacco smoking among cases of cocaine-associated 
myocardial infarction, which could suggest that tobacco use 
constitutes a favourable background for these accidents 
(Baumann et al., 2000; Hollander et al., 1995).
(10)  See the 2009 statistical bulletin for the definitions of ‘drug-related death’ by which EU Member States report to the EMCDDA. In the Netherlands, deaths 
of known problem drug users are generally not forensically examined.
(11) See ‘Drug combinations: effects and consequences’, p. 20.
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Polydrug use among drug users entering drug 
treatment 
Drug users entering treatment can be considered as indirect 
indicators of the profiles and trends in the wider population 
of problem drug users. However, it must be noted that the 
data presented here do not reflect the profile of all clients in 
treatment, but only of those starting drug treatment. 
An ad hoc data collection and analysis was carried out in 
14 European countries (12) with the objective of better 
understanding the prevalence and patterns of polydrug use 
among those entering drug treatment. The analysis was 
based on primary and secondary drugs, which were 
reported by clients only if they caused problems (according 
to the client or following a short diagnosis by a doctor) and 
had been used during the month before entering treatment. 
Alcohol was only recorded as a secondary substance in the 
framework of illicit drug treatment. Some methodological 
limitations, such as country differences in the methods of 
recording multiple drug use, must also be considered when 
interpreting the data. 
The data covered 262 477 clients who entered treatment in 
2006, with numbers in individual countries ranging from 
483 clients in Cyprus to 100 267 in England. Approximately 
50 % of all clients entered drug treatment for the first time in 
their life. The main primary drugs reported were heroin 
(47 %), cocaine (20 %), cannabis (19 %) and stimulants 
other than cocaine (4 %). The proportions are slightly 
different among the subgroup of those entering treatment for 
the first time, with heroin accounting for 36 % of new clients, 
Drug combinations: effects and consequences 
The specific risks associated with particular drug combinations 
can only be described in outline, as they are also influenced by 
characteristics of the user, such as the existence of tolerance, 
health status or genetic or phenotypic factors. Impaired liver 
functioning may, for instance, lead to higher blood 
concentrations, thereby causing increased toxic effects. The 
quantity and purity of the drugs used and the route of 
administration are other key variables that have an impact on 
the effects of drug combinations. Intravenous drug use will also 
lead to higher blood concentrations.
Despite these limitations, it is possible to list the better-
documented effects and consequences of some of the common 
drug combinations, including those associated with high risks 
and severe health problems. 
Alcohol: a cross-cutting issue in polydrug problems
Alcohol is present in most polydrug use combinations. 
Alcohol intoxication may lead to misjudgements regarding 
the use of other substances, including the amounts used. 
Concomitant alcohol use can also produce changes in the 
pharmacokinetics of other substances. Long-term, heavy use 
of alcohol is likely to cause severe liver damage, which often 
impairs the metabolism of other substances and can make it 
dangerous to consume amounts that would otherwise be 
tolerated. 
Cocaine and alcohol 
Alcohol can increase the levels of cocaine in the blood by 
about 30 %. It also enables the production of a psychoactive 
cocaine metabolite (cocaethylene) with a longer duration in the 
blood. The combination of these two substances also increases 
heart rate and blood pressure, which could lead to a higher 
risk of cardiovascular problems. In addition, cocaine use may 
facilitate increased alcohol consumption by decreasing the 
perception of alcohol intoxication effects. Violent behaviour 
and suicidal ideation have also been associated with the 
concomitant use of these two substances.
Opioids and cocaine
Opioids depress the central nervous system and cocaine 
stimulates it. The negative cardiovascular effects of cocaine are 
amplified when it is co-administered with opioids. Animal 
studies also indicate that cocaine, as well as opioids, can 
induce respiratory depression, which could increase overdose 
risk. In addition, cocaine can initially mask the sedative effects 
of opioids, thereby increasing the risk of a later overdose.
Opioids and benzodiazepines, with or without alcohol 
Opioids, benzodiazepines and alcohol are all depressants of the 
central nervous system. Their concomitant use can lead to marked 
respiratory depression resulting in a high risk of fatal and 
non-fatal overdoses. Older drug users may also face delayed 
metabolism of benzodiazepines and there is an increased danger 
of respiratory depression when used with methadone.
(12) Czech Republic, Denmark, Ireland, Greece, Spain, France, Italy, Cyprus, Latvia, Netherlands, Romania, Finland, Sweden, United Kingdom (England).
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cocaine for 28 %, cannabis for 26 % and stimulants other 
than cocaine for 5 %. There were also considerable 
differences between countries in the distribution of primary 
drugs (13) (EMCDDA, 2009a).
More than half of the clients (57 %) reported at least one 
problematic drug in addition to the primary substance for 
which they had entered treatment. These clients can be 
regarded as polydrug users. Overall, 33 % of all clients 
reported one secondary drug, 20 % reported two, and a 
much smaller proportion reported three or more secondary 
drugs. The proportion of treatment clients reporting polydrug 
use varied between countries, from 13 % in Romania to 
86 % in Finland (14). Among new clients, the figures ranged 
from 40 % in France to 81 % in Finland (15). 
The highest proportion of polydrug users was recorded 
among crack clients and among those entering treatment for 
the use of stimulants other than cocaine, but both of these 
groups were numerically small. The lowest proportion of 
polydrug users was found among primary cannabis clients. 
For all drugs with the exception of heroin, polydrug users 
composed a higher proportion of clients entering treatment 
for the first time than of all clients entering treatment. This 
might suggest a recent increase in multiple substance use 
among problem drug users.
Overall, around 60 % of clients reporting heroin, cocaine or 
other stimulants as their primary drug also reported a 
secondary drug. The proportion of polydrug users was 
smaller among cannabis users (43 %) and higher among 
crack users (69 %). These figures varied greatly between 
countries. In Romania, only 1.4 % of primary heroin users 
reported a secondary substance, while 92.2 % did so in 
Finland. For primary cannabis users, the prevalence of 
secondary drug use ranged between 23 % in Italy and 
79 % in Finland. For primary cocaine users, polydrug use 
ranged from 44 % in Italy to 83 % in Ireland; among 
primary users of non-cocaine stimulants, it ranged from 
30 % in Italy to 85 % in Finland (16).
The most frequently reported secondary drugs were cocaine 
(including crack, by 32 % of all clients reporting a 
secondary drug), alcohol (27 %), cannabis (27 %) and other 
stimulants (11 %). The frequent reporting of cocaine as a 
secondary substance might reflect increases in prevalence of 
use observed in several countries in recent years, as well as 
the use of cocaine among primary heroin users, who 
sometimes re-enter treatment for problems related to cocaine 
(SIVZ/IVZ, 2006) (17). 
Countries differed in the secondary substances most 
frequently reported. In Ireland, cocaine hydrochloride was 
reported as a secondary substance by more than one-third 
of polydrug clients (35 %), and by more than half in Cyprus 
(54 %). In the United Kingdom, crack cocaine was reported 
as a secondary drug by 29 % of those clients who reported 
use of more than one substance. Alcohol was cited as a 
secondary substance by around 40 % of drug clients in 
Denmark, Ireland, Spain and Sweden, and cannabis by 
around half of all clients in the Czech Republic and Finland, 
and by even larger proportions of clients in Cyprus (59 %) 
and Greece (63 %). Finally, stimulants other than cocaine 
were reported as a secondary drug by about one-third to a 
half of drug clients in the Czech Republic, Denmark, Cyprus, 
Latvia, Finland and Sweden.
The most frequently reported drug combinations among 
clients who entered treatment in 2006 were: heroin and 
cocaine; cocaine and cannabis; cannabis and alcohol (18). 
Each combination was sometimes reported with other 
substances.
Patients co-using heroin and cocaine (including crack) 
represented a large group of the polydrug users in 
treatment. This group was comprised largely of heroin users 
who also use cocaine, and often use other drugs including 
alcohol. The proportion of heroin and cocaine co-users 
among all clients varied from 2 % in Denmark to 38 % in 
Cyprus. Heroin and cocaine (‘speedballing’) are sometimes 
injected together. Local studies suggest that this practice can 
be popular among injecting drug users and the mixture is 
sold on drug markets (De la Fuente et al., 2005). Injecting 
heroin with crack cocaine reinforces the effects of both 
drugs. Heroin and cocaine co-users were mainly found in 
large European cities, and most clients using heroin and 
crack were reported by the United Kingdom (Connolly et al., 
2008; EMCDDA, 2009a). 
The use of cannabis as a secondary drug was common 
among primary cocaine users, especially those new to 
treatment. Among polydrug-using clients, 13 % reported 
(13) See Tables A2 and A3 in the online annex.
(14) See Figure A2 in the online annex.
(15) See Tables A4 and A5 in the online annex.
(16) See Table A7 in the online annex.
(17) See Table A9 in the online annex.
(18) See Tables A10 and A11 in the online annex.
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using cocaine and alcohol, with or without cannabis (23 % 
among new clients). The proportion of clients reporting 
co-use of cocaine and cannabis varied markedly between 
countries, with the highest levels in Spain and the 
Netherlands, where cocaine clients represented a large 
proportion of all clients. A prospective cohort study of 720 
cocaine users in the metropolitan areas of Madrid, 
Barcelona and Seville showed that almost all of them also 
used cannabis (93.6 %) (Pulido, 2009). 
Referral by the criminal justice system or pressure from social 
and family networks were among the main reasons for entry 
to treatment for many of the primary cocaine users who also 
reported co-use of alcohol or cannabis. They were mainly 
males and were reported to be socially integrated, with 
stable living conditions and regular employment. A Dutch 
analysis of treatment data reported that clients in treatment 
for use of powder cocaine, alone or in combination with 
alcohol or ‘soft’ drugs, usually have a regular job and 
income, and live in their own apartment or with their family 
(SIVZ/IVZ, 2006). However, studies in the USA show that a 
large majority of cocaine users in rehabilitation or treatment 
(up to 9 out of 10 patients) are also alcohol-dependent. In 
addition, patients who were once dependent upon both 
cocaine and alcohol, compared to those previously 
dependent upon cocaine alone, show higher risks of relapse 
into cocaine use triggered by alcohol use (Pennings, 2002).
Clients using cannabis in combination with alcohol, and 
sometimes other substances, form the last group, with 
patterns of use less risky than those of the other groups 
(EMCDDA, 2008a). Even though a large proportion of 
primary cannabis clients reported consuming only cannabis 
(57 % of all and 35 % of new cannabis clients), the number 
of those using other drugs, especially alcohol, is 
significant (19). In France, for example, where primary 
cannabis users make up a high proportion of the clients 
entering treatment, 24 % of new clients who reported using 
more than one substance were co-users of cannabis and 
alcohol. This group of clients often reported living with their 
family and, compared to the other groups in treatment, 
presented a younger and more socially integrated profile. 
Polydrug use among problem drug users in 
opioid substitution treatment
Substitution has become the treatment of choice for heroin 
dependence in most European countries. It is now estimated 
that there are 650 000 opioid users in receipt of this 
treatment in Europe, and the number is probably still 
increasing. Methadone and buprenorphine are the 
substitution drugs most often prescribed, but other drugs 
such as slow-release morphine, codeine and heroin are also 
used. Polydrug use is particularly prevalent among this 
group, and its potential dangers are compounded by the 
difficult health and social conditions typically experienced 
by substitution clients.
Several studies have shown that the prevalence of polydrug 
use, often including heavy alcohol use, is relatively high 
among clients entering substitution treatment. In Barcelona, 
more than one-third of patients were found to be polydrug 
users when they began methadone maintenance treatment 
(Puigdollers et al., 2004). A Swedish study found that about 
one-third of patients entering methadone treatment had a 
history of hospital treatment due to alcohol-related problems 
(Stenbacka et al., 2007). An Irish study revealed that 56 % 
of methadone patients were also diagnosed as alcohol-
dependent (MacManus and Fitzpatrick, 2007). 
The use of benzodiazepines is common among substitution 
treatment clients, with studies showing between 11 % and 
70 % of clients reporting current use. The proportion of 
non-medical use is, however, difficult to establish, and is 
further complicated by the fact that methadone clients 
(19) See Tables A6 and A7 in the online annex.
Interactions of substitution drugs with other 
substances
In addition to acute health problems and chronic risks, the 
use of drugs and alcohol by clients undergoing substitution 
treatment can pose specific problems due to drug 
interactions. As substitution clients constantly have a 
relatively high level of opioids in their blood, other drugs 
used may easily interact with the metabolism of the 
substitution substance, altering its bioavailability. This 
occurs because the same enzymes (cytochrome P450 
group of enzymes) are shared by methadone, 
buprenorphine and many other substances, including 
medicines. Some substances increase the metabolism of 
methadone and buprenorphine, some reduce it, and 
thereby influence the effects of these opioids; possibly 
leading to withdrawal symptoms or overmedication. 
Generally, these interactions appear to have greater effects 
on the bioavailability of methadone than on buprenorphine 
(CSAT, 2004) (see Table 5).
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experience a high rate of co-morbid psychiatric conditions, 
including anxiety (Aeschbach Jachmann et al., 2008). 
Cocaine use is relatively common among methadone 
patients in those countries where its use among the general 
population is highest, such Spain, Italy (e.g. Maremmani et 
al., 2007), the Netherlands and the United Kingdom 
(Gossop et al., 2002; Seivewright, 2006). In the 
Netherlands, half of the methadone clients reported cocaine 
as their secondary drug (IVZ, 2004). Cocaine use can also 
increase alcohol use, and about 60 % of patients in a 
methadone maintenance programme who also used crack 
cocaine reported using alcohol to come down or to temper 
the discomfort associated with stopping crack cocaine use 
(Magura and Rosenblum, 2000).
Patients in substitution treatment might use drugs, including 
heroin, for a variety of reasons. Compensation for an 
insufficient dose of the substitution medication (‘topping up’) 
is one of them, and in such cases patients can be helped to 
reduce their use of other drugs, mainly opioids, by being 
offered higher doses of the substitute (e.g. Donny et al., 
2005; Epstein at al., 2009). As best practice, it is 
recommended that methadone dose should be titrated 
according to individual need (e.g. Trafton et al., 2006). 
Individual tolerance and metabolism should be taken into 
account. Other reasons put forward for drug use in 
substitution treatment include pharmacological effects, such 
as reported higher cocaine effects under methadone 
substitution (Preston et al., 1996), the high abuse potential of 
flunitrazepam (Farré et al., 1998), pre-existing dependence 
and mental health problems.
Using other substances alongside the prescribed substitution 
medication can lead to severe acute health complications, 
including drug overdose. In addition, the use of alcohol and 
other drugs (possibly excluding cannabis — Epstein and 
Preston, 2003) during substitution treatment is associated 
with lower levels of psychosocial recovery. A substantial 
body of literature shows associations with higher levels of 
psychiatric co-morbidity, homelessness, unemployment, 
greater psychological distress, poorer social functioning, 
higher risk of relapse, lower retention rate in treatment, use 
of additional drugs, reduction in quality of life and higher 
levels of complications of existing medical problems (e.g. 
Backmund et al., 2005; Brands et al., 2008; Senbanjo et 
al., 2007). 
Problem drug users in non-treatment settings
Studies in EU countries among street drug users, users of 
low-threshold services, emergency room visitors, offenders 
and prison inmates generally report high levels of polydrug 
use among problem drug users outside treatment. In all 
those countries where trends could be observed, polydrug 
use increased between the mid 1990s and the 2000s 
(Estonia, Ireland, Luxembourg, Netherlands, Poland, 
Finland). Among the reasons suggested for this increase 
were the low quality of street drugs (Luxembourg) or the 
fact that problem drug users already had a history of 
alcohol abuse (Finland). The most frequently reported 
combinations include heroin and cocaine (Belgium, 
Portugal, Italy), heroin and crack cocaine (United 
Kingdom), opioids (including heroin, fentanyl and poppy 
liquid) and amphetamines (Estonia) (Talu et al., 2009), 
amphetamines and heroin (Latvia), buprenorphine and 
amphetamine or methamphetamine (Finland), and alcohol 
and stimulants (Netherlands). It is unclear from the 
Table 5: Drug interactions with methadone
Substance group Interactions
Opioid antagonists  
(including partial antagonists)
Contraindicated with methadone as they may precipitate opioid withdrawal.
Opioids
Share common metabolic pathway with methadone. The additive opioids effect  
can result in overdose. Heroin reduces methadone bioavailability.
Cannabis Possible interaction due to common metabolic pathway.
Benzodiazepines
As they may cause additive central nervous system depression this combination  
is risky and can be fatal.
Cocaine Generally reduces the effect of methadone.
Alcohol (chronic use) Reduces the effect of methadone due to enzymatic induction.
Alcohol (acute use)
Increases methadone effect (again, can add to central nervous system depression  
and there is a risk of fatal outcome).
Source: Leavitt, 2006.
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available data whether different drugs were used 
simultaneously, successively or simply within the same time 
period (e.g. one month). 
In Norway, a large study among clients of needle and 
syringe programmes showed that many problem opioid and 
amphetamine users had also used drugs such as 
psychoactive medicines (75 %), cannabis (85 %) and 
alcohol (50 %) during the month preceding the interview.
Responding to polydrug use among 
problem drug users
The range of services and interventions is generally the 
same for both polydrug and single drug use problems. The 
available interventions include harm-reduction approaches 
and psychosocial or pharmacologically assisted treatment. 
Professionals seeking information on how to manage 
polydrug-using patients have to rely on their own experience 
or that of their peers, or on case studies reported in the 
literature (Kenna et al., 2007).
Treatment
The treatment literature generally focuses on the 
management of one particular problem substance, with little 
information available on the management of problems 
related to the co-use of several substances (Rigter et al., 
2004). However, findings from large national treatment 
outcome studies provide an indication of the prevalence of 
problem polydrug use among treatment clients. Most studies 
have observed positive changes, as indicated by substantial 
reductions in the proportion of clients using several 
substances.
Results from the United Kingdom National Treatment 
Outcome Research Study (NTORS) showed that clients, most 
of whom had a heroin problem and were in residential 
treatment programmes or on outpatient methadone 
maintenance treatment programmes, significantly reduced 
their use of several substances including heroin, crack 
cocaine, non-prescribed methadone and benzodiazepines 
(Gossop et al., 2002). Furthermore, a substantial number of 
clients remained abstinent from these substances for at least 
three months prior to the two-year follow-up: over a third of 
the clients from the residential programmes and about a 
quarter of those in methadone maintenance. 
Similarly, results from VEdeTTE, a large Italian cohort study 
of 7 224 clients in continuous treatment for heroin 
dependence, showed a substantial reduction in polydrug 
use over time. The proportion of these clients who reported 
the use of cocaine as the only other drug fell from 28.1 % in 
the first month of treatment to 11.9 % after two years, while 
co-use of heroin and cocaine fell from 26.9 % to 8.4 % 
(Bargagli et al., 2006). The Australian treatment outcome 
study of clients with heroin dependence also observed 
significant reductions among all treatment modalities, one 
year after treatment intake, in the use of drugs alongside 
heroin (Teesson et al., 2006). 
Although the study designs (e.g. a lack of randomisation of 
the clients) do not allow the observed changes to be directly 
attributed to treatment effects, the results indicate that 
treatment can bring about positive changes in polydrug use 
in severe and long-term problem drug users.
Reviews of randomised controlled studies have also 
demonstrated the beneficial impact of pharmacological and 
psychosocial interventions on polydrug use. Most of the 
randomised controlled studies of opioid substitution 
treatment for heroin dependence reviewed by Gowing et al. 
(2008) reported a significant reduction in cocaine use. 
Another review found that users were more likely to remain 
abstinent from cocaine use if given high rather than low 
doses of methadone (Faggiano et al., 2003). In addition, a 
review on pharmacotherapies for several patterns of 
polydrug use indicated that disulfiram and tiagabine showed 
positive results in the management of cocaine dependence 
among clients in substitution treatment (Kenna et al., 2007), 
although the efficacy of their use for the treatment of 
primary cocaine dependence is not conclusive. 
Clinical trials have also shown that psychosocial 
interventions can in their own right contribute to reducing 
polydrug use among treatment clients, especially stimulant 
use among clients in substitution treatment. Thus, a meta-
analysis of randomised controlled studies of psychosocial 
interventions conducted by NICE (2007) revealed that 
contingency management leads to significant reductions in 
illicit drug use (including both opioids and cocaine) among 
polydrug clients in methadone maintenance treatment 
programmes, both during treatment and at follow-up. In 
Europe, the United Kingdom has started introducing 
contingency management in its treatment services. The 
Netherlands is piloting this intervention and, according to 
the 2008 national report, first results of a randomised 
controlled study investigating the efficacy of contingency 
management among clients in methadone maintenance 
treatment with cocaine problems show significantly higher 
levels of abstinence from cocaine compared with the control 
group. 
Despite these positive findings, the management of polydrug 
use remains a complex and challenging task for 
professionals. Among the factors that can render the 
treatment of clients with multiple drug use particularly 
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difficult is the severity of polydrug use at treatment intake, 
which has been shown to negatively affect the reduction of 
multiple drug consumption over time (Teesson et al., 2006). 
Polydrug clients may also conceal occasional or regular use 
of illicit drugs in order to avoid repercussions, such as 
revocation of taking home doses of substitution medication. 
In turn, clinicians are sometimes reluctant to confront patients 
with their suspicions about ongoing drug use, fearing that 
the confrontation will compromise their relationship (Bruce 
and Altice, 2007).
Drug treatment services may focus primarily on the 
management of the most problematic drugs for the client, 
usually opioids, or may not be properly equipped to address 
other substance-related problems (Körkel and Waldvogel, 
2008). This appears to be especially the case for alcohol, 
as indicated by the NTORS study, which showed that the 
prevalence of heavy alcohol use among clients in 
methadone treatment remained unchanged at two-year 
follow-up after treatment intake. In addition, the lack of 
evidence of effectiveness for treatments of particular drug 
problems, such as stimulant dependence, further contributes 
to the difficulty of effectively managing multiple drug 
problems simultaneously.
Harm reduction
Harm-reduction services for problematic drug users usually 
address the associated harms and risk behaviours, such as 
injecting, with a holistic approach that focuses on the 
nature and severity of the behaviours and problems 
experienced by the individual, rather than on a specific 
substance. Therefore, in response to the elevated health 
risks associated with problem drug use, including polydrug 
use, harm-reduction services are generally provided on a 
case-by-case basis and often according to professionals’ 
own work experience. Furthermore, harm-reduction 
interventions usually operate within a broader local 
prevention strategy that combines other types of services 
such as outreach work and opioid substitution treatment, 
which contribute to the reduction of risks and health 
problems experienced by problem polydrug users. Evidence 
of the effectiveness of harm-reduction interventions has 
been reported in other EMCDDA publications (EMCDDA, 
2008a) and will be reviewed in a forthcoming monograph 
on harm reduction. 
Member States provide a wide range of harm-reduction 
services that aim to minimise the health consequences and 
risk behaviours of problem drug users, including problem 
polydrug users. These interventions include safer-use 
training, needle and syringe exchange, infectious diseases 
testing and counselling, hepatitis B vaccination and 
treatment of viral hepatitis and HIV infection. Client 
healthcare assessments, which identify individual harm-
reduction needs, are also provided and appropriate 
information, advice and basic healthcare are subsequently 
offered. Among the most problematic and marginalised 
users, the primary focus will be on minimising the most acute 
health risks, which are usually injecting and overdose risks. 
Chronic health consequences associated with the concurrent 
use of tobacco, cannabis or alcohol may be of secondary 
importance, depending on the severity of the cases and on 
the level of acute risk-taking. Targeted information and 
education materials for specific polydrug consumption 
patterns have also recently been developed. 
Conclusions
This overview of polydrug use among adolescents, young 
adults and problem drug users has shown that the use of 
multiple substances is a widespread pattern of drug use in 
Europe and carries particular health risks. Polydrug use 
reflects both the increasingly wide range of drugs available 
and the willingness of different groups of young people to 
experiment in the use of psychoactive substances. In 
addition, drug-taking repertoires have become both complex 
and dynamic, influenced by individual rituals, social 
controls, rationales and beliefs, the context in which drugs 
are used, the sought-after effects, and the extent to which 
individuals are dependent or experiencing problems. 
Risk-taking is associated with a complex picture of 
interrelated issues, including the frequency and quantity of 
the drugs taken. And, any attempt to describe, let alone 
quantify, it cannot be accomplished simply by listing the 
distinct risks of each substance or a particular drug 
combination. We must consider the many and various 
interconnections. 
Polydrug use can have many different forms: among 15- to 
16-year-old school children, about one in four had used 
both alcohol and tobacco in the last 30 days and a very 
small proportion had used two or more illicit drugs. Among 
young adults, the analysis of data for last year prevalence of 
substance use in nine countries showed associations 
between frequent and heavy alcohol use and cannabis or 
cocaine use. This is corroborated by studies in nightlife 
settings which observe similar associations. Finally, data 
from treatment settings and other sources point to the 
existence of three distinct populations of problem polydrug 
users. The first of these is composed of co-users of heroin 
and cocaine, who are often marginalised. The other groups, 
more recently identified, are made up of more socially 
integrated cocaine inhalers and alcohol users, and of 
younger co-users of cannabis and alcohol.
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The presence of alcohol in almost all of the polydrug-use 
repertoires and among all of the different populations 
addressed is one of the key findings of this ‘Selected issue’. 
Alcohol is almost always the first drug with strong 
psychoactive and mind-altering effects used by young 
people, and its widespread availability makes it the 
ever-present drug in substance combinations among young 
adults, particularly in recreational settings. Alcohol is also a 
fundamental component of most polydrug use profiles 
among problem drug users; and this suggests that there is a 
need for additional interventions targeting alcohol, both at 
the market level and at the level of social norms. Tobacco 
smoking may also be a basic component of many polydrug 
use profiles, although it was not recorded in all the data 
sets. There is evidence that recent measures such as smoking 
and advertisement bans and tax increases have been 
effective in reducing overall cigarette consumption. While 
the acute, adverse effects of polydrug use may be limited to 
smaller populations of high-risk, vulnerable and problem 
drug users, some patterns of use may, like the widespread 
use of cigarettes in the past, carry long-term, adverse health 
consequences that go unacknowledged due to widespread 
social acceptance and vested economic interests.
This exploration of polydrug use also highlights the influence 
of social context on patterns of use. It was observed, both 
among adolescents and young adults, that in countries with 
low drug use prevalence, people who use cannabis, for 
example, tend to deviate much more from the general 
population, in terms of other drug use, than their 
counterparts in high-prevalence countries. It is important to 
identify and target interventions at the minority of vulnerable 
young potential ‘problem’ users who make ill-considered 
decisions about drug taking and are likely to go on to 
experience problems with their drug use. The early 
identification of these vulnerable people may not always be 
by their cannabis use, for example. Rather, they should be 
identified in the context of a wider understanding of drug 
use and social factors, so that targeted interventions take 
into account national characteristics in vulnerability, patterns 
of substance use and drug availability. 
Polydrug use is very common among problem drug users, 
although its prevalence and specific pattern may differ 
between countries. Among this group, the use of multiple 
drugs generally aggravates an already difficult condition 
and leads to increased risk-taking. The most severe 
consequences of these patterns of use include fatal and 
non-fatal overdoses, hepatotoxicity — especially in 
combination with hepatitis C infection — and compromised 
outcomes of treatment efforts.
Information on current treatment practices in the Member 
States and on the management of polydrug use is limited. 
Generally, reports in the treatment literature focus on the 
management of problems related to individual substances, 
mostly opioids or stimulants, with little information on the 
management of those related to multiple substance use. 
While it is generally assumed that polydrug use is a 
hard-to-treat condition, results from large treatment 
outcome studies in Europe show significant reductions in 
multiple drug use among highly problematic users. 
Nevertheless, managing the care of problem polydrug 
users requires long-term treatment planning with attention 
to individual needs and multidisciplinary teams working 
together with flexible and sometimes innovative treatment 
options.
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